転移性切除不能中腸神経内分泌腫瘍患者における 177Lu-DOTATATE PRRT とエベロリムスの再治療の比較、NET RETREAT 試験
NET RETREAT: 転移性/切除不能中腸 NET における 177 ルテチウム-DOTATATE 再治療とエベロリムスの第 II 相試験
This phase II trial compares the effect of retreatment with 177Lu-DOTATATE peptide receptor radionuclide therapy (PRRT) to the usual approach of treatment with everolimus, sunitinib, or cabozantinib in patients who have previously received 177Lu-DOTATATE for gastroenteropancreatic neuroendocrine tumor (GEPNET) that has spread from where it first started (primary site) to other places in the body (metastatic) and that cannot be removed by surgery (unresectable). PRRT is a type of radiation therapy for which a radioactive chemical is linked to a peptide (small protein) that targets tumor cells. When this radioactive peptide is injected into the body, it binds to a specific receptor found on some tumor cells. The radioactive peptide builds up in these cells and helps kill the tumor cells without harming normal cells. In this trial 177Lu-DOTATATE is used for PRRT. 177Lu-DOTATATE PRRT may increase the length of time until worsening of the GEPNET compared to the usual approach. Everolimus is in a class of medications called kinase inhibitors. It is also a type of angiogenesis inhibitor. Everolimus works by stopping tumor cells from reproducing and by decreasing blood supply to the tumor cells. Sunitinib and cabozantinib, block certain proteins, which may help keep tumor cells from growing. They may also prevent the growth of new blood vessels that tumors need to grow. Sunitinib malate is a type of tyrosine kinase inhibitor and a type of antiangiogenesis agent. Retreating with 177Lu-DOTATATE may work better than everolimus, sunitinib or cabozantinib in shrinking or stabilizing tumors in patients with metastatic and unresectable GEPNET who were previously treated with 177Lu-DOTATATE.
調査の概要
状態
詳細な説明
PRIMARY OBJECTIVE:
I. To evaluate the effect of lutetium Lu 177 dotatate (177Lu-DOTATATE) versus (vs.) everolimus or sunitinib (for pancreatic neuroendocrine [NET] patients only) or cabozantinib (United States [US] patients only) on progression-free survival (PFS) in patients with metastatic/unresectable GEPNET who have progressed following previous peptide receptor radionuclide therapy (PRRT).
SECONDARY OBJECTIVES:
I. To evaluate the toxicity and safety of 177Lu-DOTATATE and everolimus or sunitinib (for pancreatic neuroendocrine NET patients only) or cabozantinib (US patients only).
II. To determine the effect of 177Lu-DOTATATE vs. everolimus or sunitinib (for pancreatic neuroendocrine NET patients only) or cabozantinib (US patients only) on overall response rate (ORR).
III. To evaluate the effect of 177Lu-DOTATATE vs. everolimus or sunitinib (for pancreatic neuroendocrine NET patients only) or cabozantinib (US patients only) on overall survival (OS).
IV. To evaluate post progression survival (PPS) and time to second objective disease progression (PFS2) for patients randomized to Arm 2 of the study and crossed over to Arm 1 at time of objective progression per Response Evaluation Criteria in Solid Tumors (RECIST) 1.1.
V. To evaluate the effect of 177Lu-DOTATATE vs. everolimus or sunitinib (for pancreatic neuroendocrine NET patients only) or cabozantinib (US patients only) on patient quality of life (QoL).
OUTLINE: Patients are randomized to 1 of 2 arms.
ARM I: Patients receive 177Lu-DOTATATE intravenously (IV) over 30 minutes every 8 weeks (Q8W). Treatment repeats for two cycles in the absence of disease progression or unacceptable toxicities. Patients also undergo computed tomography (CT) scan and/or magnetic resonance imaging (MRI) and collection of blood samples while on study.
ARM II: Patients receive everolimus orally (PO) on a daily basis (QD), sunitinib PO QD or cabozantinib PO QD. Treatment continues in the absence of disease progression or unacceptable toxicities. Patients whose cancer worsens may cross over to ARM I. Patients also undergo CT scan and/or MRI and collection of blood samples while on study.
After completion of study treatment, patients are followed up every 12 weeks until objective disease progression and then every 6 months until death.
研究の種類
入学 (推定)
段階
- フェーズ2
連絡先と場所
研究場所
-
-
Alabama
-
Birmingham、Alabama、アメリカ、35233
- 一時停止
- University of Alabama at Birmingham Cancer Center
-
-
Arizona
-
Phoenix、Arizona、アメリカ、85054
- 募集
- Mayo Clinic Hospital in Arizona
-
コンタクト:
- Site Public Contact
- 電話番号:855-776-0015
-
主任研究者:
- Patrick W. McGarrah
-
Tucson、Arizona、アメリカ、85719
- 募集
- Banner University Medical Center - Tucson
-
コンタクト:
- Site Public Contact
- メール:UACC-IIT@uacc.arizona.edu
-
主任研究者:
- Rachna T. Shroff
-
Tucson、Arizona、アメリカ、85719
- 募集
- University of Arizona Cancer Center-North Campus
-
コンタクト:
- Site Public Contact
- メール:UACC-IIT@uacc.arizona.edu
-
主任研究者:
- Rachna T. Shroff
-
-
California
-
San Francisco、California、アメリカ、94158
- 募集
- UCSF Medical Center-Mission Bay
-
コンタクト:
- Site Public Contact
- 電話番号:877-827-3222
- メール:cancertrials@ucsf.edu
-
主任研究者:
- Aman Chauhan
-
-
Colorado
-
Aurora、Colorado、アメリカ、80045
- 募集
- UCHealth University of Colorado Hospital
-
コンタクト:
- Site Public Contact
- 電話番号:720-848-0650
-
主任研究者:
- Emily Baiyee-Toegel
-
-
Florida
-
Aventura、Florida、アメリカ、33180
- 募集
- UM Sylvester Comprehensive Cancer Center at Aventura
-
コンタクト:
- Site Public Contact
- 電話番号:954-461-2180
-
主任研究者:
- Gretel Terrero
-
Coral Gables、Florida、アメリカ、33146
- 募集
- UM Sylvester Comprehensive Cancer Center at Coral Gables
-
コンタクト:
- Site Public Contact
- 電話番号:305-243-2647
-
主任研究者:
- Gretel Terrero
-
Deerfield Beach、Florida、アメリカ、33442
- 募集
- UM Sylvester Comprehensive Cancer Center at Deerfield Beach
-
コンタクト:
- Site Public Contact
- 電話番号:305-243-2647
-
主任研究者:
- Gretel Terrero
-
Jacksonville、Florida、アメリカ、32224-9980
- 募集
- Mayo Clinic in Florida
-
コンタクト:
- Site Public Contact
- 電話番号:855-776-0015
-
主任研究者:
- Patrick W. McGarrah
-
Miami、Florida、アメリカ、33136
- 募集
- University of Miami Miller School of Medicine-Sylvester Cancer Center
-
コンタクト:
- Site Public Contact
- 電話番号:305-243-2647
-
主任研究者:
- Gretel Terrero
-
Miami、Florida、アメリカ、33176
- 募集
- UM Sylvester Comprehensive Cancer Center at Kendall
-
コンタクト:
- Site Public Contact
- 電話番号:305-243-2647
-
主任研究者:
- Gretel Terrero
-
North Miami、Florida、アメリカ、33181
- 募集
- University of Miami Sylvester Comprehensive Cancer Center at Sole Mia
-
主任研究者:
- Gretel Terrero
-
コンタクト:
- Site Public Contact
- メール:kginnity@med.miami.edu
-
Plantation、Florida、アメリカ、33324
- 募集
- UM Sylvester Comprehensive Cancer Center at Plantation
-
コンタクト:
- Site Public Contact
- 電話番号:305-243-2647
-
主任研究者:
- Gretel Terrero
-
-
Illinois
-
Chicago、Illinois、アメリカ、60637
- 募集
- University of Chicago Comprehensive Cancer Center
-
コンタクト:
- Site Public Contact
- 電話番号:773-702-8222
- メール:cancerclinicaltrials@bsd.uchicago.edu
-
主任研究者:
- Chih-Yi Liao
-
Chicago、Illinois、アメリカ、60611
- 募集
- Northwestern University
-
主任研究者:
- Al B. Benson
-
コンタクト:
- Site Public Contact
- 電話番号:312-695-1301
- メール:cancer@northwestern.edu
-
DeKalb、Illinois、アメリカ、60115
- 募集
- Northwestern Medicine Cancer Center Kishwaukee
-
主任研究者:
- Al B. Benson
-
コンタクト:
- Site Public Contact
- 電話番号:630-352-5360
- メール:Donald.Smith3@nm.org
-
Geneva、Illinois、アメリカ、60134
- 募集
- Northwestern Medicine Cancer Center Delnor
-
主任研究者:
- Al B. Benson
-
コンタクト:
- Site Public Contact
- 電話番号:630-352-5360
- メール:Donald.Smith3@nm.org
-
New Lenox、Illinois、アメリカ、60451
- 募集
- UC Comprehensive Cancer Center at Silver Cross
-
コンタクト:
- Site Public Contact
- 電話番号:773-702-8222
- メール:cancerclinicaltrials@bsd.uchicago.edu
-
主任研究者:
- Chih-Yi Liao
-
Oak Brook、Illinois、アメリカ、60523
- 募集
- Northwestern Medicine Oak Brook
-
主任研究者:
- Al B. Benson
-
コンタクト:
- Site Public Contact
- メール:nctnprogram_rhlccc@northwestern.edu
-
Orland Park、Illinois、アメリカ、60462
- 募集
- University of Chicago Medicine-Orland Park
-
コンタクト:
- Site Public Contact
- 電話番号:773-702-8222
- メール:cancerclinicaltrials@bsd.uchicago.edu
-
主任研究者:
- Chih-Yi Liao
-
Warrenville、Illinois、アメリカ、60555
- 募集
- Northwestern Medicine Cancer Center Warrenville
-
主任研究者:
- Al B. Benson
-
コンタクト:
- Site Public Contact
- 電話番号:630-352-5360
- メール:Donald.Smith3@nm.org
-
-
Indiana
-
Crown Point、Indiana、アメリカ、46307
- 募集
- UChicago Medicine Northwest Indiana
-
主任研究者:
- Chih-Yi Liao
-
コンタクト:
- Site Public Contact
- 電話番号:855-702-8222
- メール:cancerclinicaltrials@bsd.uchicago.edu
-
-
Iowa
-
Ankeny、Iowa、アメリカ、50023
- 募集
- UI Health Care Mission Cancer and Blood - Ankeny Clinic
-
コンタクト:
- Site Public Contact
- 電話番号:515-241-3305
-
主任研究者:
- Seema Harichand-Herdt
-
Clive、Iowa、アメリカ、50325
- 募集
- UI Health Care Mission Cancer and Blood - West Des Moines Clinic
-
コンタクト:
- Site Public Contact
- 電話番号:515-241-3305
-
主任研究者:
- Seema Harichand-Herdt
-
Des Moines、Iowa、アメリカ、50309
- 募集
- Iowa Methodist Medical Center
-
コンタクト:
- Site Public Contact
- 電話番号:515-241-6727
-
主任研究者:
- Seema Harichand-Herdt
-
Des Moines、Iowa、アメリカ、50309
- 募集
- UI Health Care Mission Cancer and Blood - Des Moines Clinic
-
コンタクト:
- Site Public Contact
- 電話番号:515-241-3305
-
主任研究者:
- Seema Harichand-Herdt
-
Des Moines、Iowa、アメリカ、50314
- 募集
- UI Health Care Mission Cancer and Blood - Laurel Clinic
-
コンタクト:
- Site Public Contact
- 電話番号:515-241-3305
-
主任研究者:
- Seema Harichand-Herdt
-
Waukee、Iowa、アメリカ、50263
- 募集
- UI Health Care Mission Cancer and Blood - Waukee Clinic
-
コンタクト:
- Site Public Contact
- 電話番号:515-241-3305
-
主任研究者:
- Seema Harichand-Herdt
-
-
Kentucky
-
Lexington、Kentucky、アメリカ、40536
- 積極的、募集していない
- University of Kentucky/Markey Cancer Center
-
-
Michigan
-
Detroit、Michigan、アメリカ、48202
- 積極的、募集していない
- Henry Ford Hospital
-
-
Minnesota
-
Rochester、Minnesota、アメリカ、55905
- 募集
- Mayo Clinic in Rochester
-
コンタクト:
- Site Public Contact
- 電話番号:855-776-0015
-
主任研究者:
- Patrick W. McGarrah
-
-
New Mexico
-
Albuquerque、New Mexico、アメリカ、87106
- 募集
- University of New Mexico Cancer Center
-
コンタクト:
- Site Public Contact
- 電話番号:505-925-0348
- メール:HSC-ClinicalTrialInfo@salud.unm.edu
-
主任研究者:
- Bernard Tawfik
-
-
New York
-
Rochester、New York、アメリカ、14642
- 募集
- University of Rochester
-
コンタクト:
- Site Public Contact
- 電話番号:585-275-5830
-
主任研究者:
- Haoming Qiu
-
-
Ohio
-
Columbus、Ohio、アメリカ、43210
- 募集
- Ohio State University Comprehensive Cancer Center
-
コンタクト:
- Site Public Contact
- 電話番号:800-293-5066
- メール:Jamesline@osumc.edu
-
主任研究者:
- Bhavana Konda
-
-
Utah
-
Salt Lake City、Utah、アメリカ、84112
- 募集
- Huntsman Cancer Institute/University of Utah
-
コンタクト:
- Site Public Contact
- 電話番号:888-424-2100
- メール:cancerinfo@hci.utah.edu
-
主任研究者:
- Heloisa P. Soares
-
-
-
-
British Columbia
-
Vancouver、British Columbia、カナダ、V5Z 4E6
- 募集
- BCCA-Vancouver Cancer Centre
-
コンタクト:
- Site Public Contact
- 電話番号:888-939-3333
-
主任研究者:
- Jonathan M. Loree
-
-
Manitoba
-
Winnipeg、Manitoba、カナダ、R3E 0V9
- 募集
- CancerCare Manitoba
-
コンタクト:
- Site Public Contact
- 電話番号:866-561-1026
- メール:ctu_web@cancercare.mb.ca
-
主任研究者:
- Hanbo Zhang
-
-
Newfoundland and Labrador
-
St. John's、Newfoundland and Labrador、カナダ、A1B 3V6
- 募集
- Doctor H. Bliss Murphy Cancer Centre
-
コンタクト:
- Site Public Contact
- 電話番号:709-777-7589
-
主任研究者:
- Renee Lester
-
-
Ontario
-
London、Ontario、カナダ、N6A 4L6
- 募集
- London Regional Cancer Program
-
コンタクト:
- Site Public Contact
- 電話番号:519-685-8600
-
主任研究者:
- David Laidley
-
Ottawa、Ontario、カナダ、K1H 8L6
- 募集
- Ottawa Hospital and Cancer Center-General Campus
-
コンタクト:
- Site Public Contact
- 電話番号:613-761-4395
-
主任研究者:
- Timothy R. Asmis
-
Toronto、Ontario、カナダ、M4N 3M5
- 募集
- Odette Cancer Centre- Sunnybrook Health Sciences Centre
-
コンタクト:
- Site Public Contact
- 電話番号:416-480-5000
-
主任研究者:
- Simron Singh
-
-
Quebec
-
Québec、Quebec、カナダ、G1R 2J6
- 募集
- CHU de Quebec-L'Hotel-Dieu de Quebec (HDQ)
-
コンタクト:
- Site Public Contact
- メール:rechclinique@crchuq.ulaval.ca
-
主任研究者:
- Jean-Mathieu Beauregard
-
-
参加基準
適格基準
就学可能な年齢
健康ボランティアの受け入れ
受講資格のある性別
説明
Inclusion Criteria:
-
Patients must be at least >= 18 years of age
-
Metastatic, histologically confirmed grade 1 or 2 well-differentiated gastroenteropancreatic neuroendocrine tumours, including NETs of unknown primary thought to be of gastroenterogancreatic origin, with positive Gallium-68 DOTATATE scan, Copper-64 DOTATATE scan or octreotide scan within the last 12 months is recommended but within the last 36 months is allowed. Lesions on Gallium-68 or Copper-64 DOTATATE scan or octreotide scan will be considered positive if the maximum standardized uptake value (SUVmax) of target lesion is > SUV mean of normal liver parenchyma
- 7th Edition of the TNM Classification of Malignant Tumours
-
Have received 3 or 4 cycles of PRRT using 177Lu-DOTATATE or a cumulative exposure of 22,200 MBq (600mCi) or 29,600 MBq (800 mCi) within +/- 10% variation within a 52-week period. No previous targeted alpha therapy is permitted
-
Have had radiological progression per RECIST 1.1 after prior PRRT treatment and no sooner than 12 months from last scan performed post completion of initial PRRT where either stable disease, partial response, or complete response has been maintained throughout. Patients may have received previous systemic anti-cancer therapy subsequently, as long as they had benefited from initial PRRT for at least 12 months and have had confirmed progression per RECIST 1.1 on the intervening systemic anti-cancer therapy. Somatostatin analogues (SSA) administered for functional control are not considered an intervening systemic anti-cancer therapy. If intervening systemic anti-cancer therapy included a vascular endothelial growth factor (VEGF)-inhibitor, sunitinib can not be selected as standard of care on Arm 2. If intervening systemic anti-cancer therapy included an mammalian target of rapamycin (mTOR)-inhibitor, then everolimus can not be selected as the standard of care on Arm 2. If the intervening therapy is an alkylating agent, exposure of alkylating agent cannot exceed 12 months. The 12-month limit will also be applied to pre PRRT alkylator use as well
-
Patients may have received previous ablative therapy or bland embolization as liver directed therapy however this must not have been received within 12 weeks from randomization date. Previous chemo and radio embolization are not permitted. Any lesion treated with an ablative technique as well as lesions in the lobe(s) of the liver treated with embolization shall not be included in target lesion assessment unless they have since progressed
-
No ongoing toxicity from prior PRRT that is grade 3 or higher according to Common Terminology Criteria for Adverse Events (CTCAE) 5.0
-
Eastern Cooperative Oncology Group (ECOG) performance status =< 2
-
Hemoglobin >= 80 g/L (>= 8.0 g/dL) (measured within 28 days prior to enrollment)
-
Absolute neutrophil count >= 1.0 x 10^9/L (>= 1000/mm^3) (measured within 28 days prior to enrollment)
-
Platelets >= 80 x 10^9/L (>= 80 x 10^3/mm^3) (measured within 28 days prior to enrollment)
-
Total bilirubin < 1.5 x upper limit of normal (ULN) (upper limit of normal) (measured within 28 days prior to enrollment)
- If confirmed Gilbert's, eligible providing =< 3.0 x ULN
-
Creatinine clearance > 50 mL/min (measured within 28 days prior to enrollment)
- Creatinine clearance to be measured directly by 24 hour urine sampling or as calculated by Cockcroft and Gault equation
-
Prior or current use of somatostatin analogues is allowed for carcinoid syndrome control or in PRRT re-treatment patient population (Arm 1). Patients randomized to Arm 2 and receiving everolimus or sunitinib (pancreatic NET patients only) or cabozantinib (US patients only) will not be allowed to continue somatostatin analogues unless they have functional syndrome
-
Patient consent must be appropriately obtained in accordance with applicable local and regulatory requirements. Each patient must sign a consent form prior to enrollment in the trial to document their willingness to participate
-
Males and females of reproductive potential must have agreed to use a highly effective contraceptive method during protocol treatment and for 7 months after the last dose of protocol treatment for females and 4 months after the last dose of protocol treatment for males. A woman is considered to be of "childbearing potential" if she has had menses at any time in the preceding 12 consecutive months. In addition to routine contraceptive methods, "effective contraception" also includes heterosexual celibacy and surgery intended to prevent pregnancy (or with a side-effect of pregnancy prevention) defined as a hysterectomy, bilateral oophorectomy or bilateral tubal ligation, or vasectomy/vasectomized partner. However, if at any point a previously celibate patient chooses to become heterosexually active during the time period for use of contraceptive measures outlined in the protocol, he/she is responsible for beginning contraceptive measures. Men should avoid fathering a child for 4 months after the last dose of 177Lu-DOTATATE
- Women of childbearing potential will have a pregnancy test to determine eligibility as part of the Pre-Study Evaluation; this may include an ultrasound to rule-out pregnancy if a false-positive is suspected. For example, when beta-human chorionic gonadotropin is high and partner is vasectomized, it may be associated with tumour production of human chorionic gonadotropin (hCG), as seen with some cancers. Patient will be considered eligible if an ultrasound is negative for pregnancy
-
Patients must be accessible for treatment, response assessment, and follow up. Patients enrolled on this trial must be treated and followed at the participating center. Investigators must assure themselves the patients enrolled on this trial will be available for complete documentation of the treatment, adverse events, and follow-up
- Patients must agree to return to their primary care facility for any adverse events which may occur through the course of the trial
-
Patient must have access to everolimus or sunitinib (pancreatic NET patients only) or cabozantinib (US patients only). In the event that site/investigator is unable to provide access to the drug, patient will not be eligible for this trial
-
Human immunodeficiency virus (HIV) infected patients on effective anti-retroviral therapy with undetectable viral load within 6 months are eligible for this trial
-
Patients with a prior or concurrent malignancy whose natural history or treatment does not have the potential to interfere with the safety or efficacy assessment of the investigational regimen are eligible for this trial
Exclusion Criteria:
- Major surgical procedures within 6 weeks from randomization date
- Known brain metastases, unless these metastases have been treated, stabilized and off steroids for at least 4 weeks prior to enrollment in the study. Patients with a history of brain metastases must have a head CT and/or MRI with contrast to document stable disease prior to enrollment in the study
- Uncontrolled congestive heart failure no worse than New York Heart Association Class (NYHA) IIB
- Inability to swallow oral medications or gastrointestinal disease limiting absorption of oral agents
- Patients with any other significant medical or surgical condition, currently uncontrolled by treatment, which may interfere with completion of the study
- Pregnant women are excluded from this study because 177Lu-DOTATATE is a peptide receptor radionuclide therapy with the potential for teratogenic or abortifacient effects. Because there is an unknown but potential risk for adverse events in nursing infants secondary to treatment of the mother with 177Lu-DOTATATE, breastfeeding should be discontinued if the mother is treated with everolimus or sunitinib or cabozantinib (US patients only) and for 2.5 months following the last treatment with 177Lu-DOTATATE
研究計画
研究はどのように設計されていますか?
デザインの詳細
- 主な目的:処理
- 割り当て:ランダム化
- 介入モデル:並列代入
- マスキング:なし(オープンラベル)
武器と介入
参加者グループ / アーム |
介入・治療 |
|---|---|
|
実験的:Arm I (177Lu-DOTATATE)
Patients receive 177Lu-DOTATATE IV over 30 minutes Q8W. Treatment repeats for two cycles in the absence of disease progression or unacceptable toxicities. Patients also undergo CT scan and/or MRI and collection of blood samples while on study. |
Ancillary studies
他の名前:
Undergo MRI
他の名前:
Ancillary studies Undergo collection of blood samples
他の名前:
Undergo CT scan
他の名前:
Given IV
他の名前:
|
|
アクティブコンパレータ:Arm II (everolimus)
Patients receive everolimus PO QD, sunitinib PO QD or cabozantinib PO QD. Treatment continues in the absence of disease progression or unacceptable toxicities. Patients whose cancer worsens may cross over to ARM I. Patients also undergo CT scan and/or MRI and collection of blood samples while on study. |
Ancillary studies
他の名前:
Undergo MRI
他の名前:
Ancillary studies Undergo collection of blood samples
他の名前:
Undergo CT scan
他の名前:
Given PO Given PO
他の名前:
Given PO |
この研究は何を測定していますか?
主要な結果の測定
結果測定 |
メジャーの説明 |
時間枠 |
|---|---|---|
|
Progression-free survival (PFS)
時間枠:From randomization to any documented evidence of tumour progression or death from any cause, assessed up to 3 years
|
The PFS of patients of both treatment groups will be described by Kaplan-Meier method and the median PFS will be estimated using the same method. A one-sided stratified log-rank test adjusting for the stratification factor at randomization will be the primary method to compare the difference in PFS between the experimental and control treatments, at the 5% level. A stratified Cox model adjusting for duration of durable response to the initial peptide receptor radionuclide therapy (durable response >= 24 months versus [vs.] < 24 months) at randomization and with one single treatment covariate will be used to estimate the hazard ratio and associated one-sided 95% confidence interval. Sensitivity analysis adjusting for all three stratification factors at randomization will also be performed. |
From randomization to any documented evidence of tumour progression or death from any cause, assessed up to 3 years
|
二次結果の測定
結果測定 |
メジャーの説明 |
時間枠 |
|---|---|---|
|
Overall survival (OS)
時間枠:From randomization to death from any cause, assessed up to 3 years
|
The OS of patients of both treatment groups will be described by Kaplan-Meier method and the median OS will be estimated using the same method. A one-sided stratified log-rank test adjusting for the stratification factor at randomization will be the primary method to compare the difference in OS between the experimental and control treatments, at the 5% level. A stratified Cox model adjusting for the stratification factor at randomization and with one single treatment covariate will be used to estimate the hazard ratio and associated one-sided 95% confidence interval. |
From randomization to death from any cause, assessed up to 3 years
|
|
Objective response rate (ORR)
時間枠:Up to 3 years
|
Defined as the proportion of patients with a documented complete response and partial response based on Response Evaluation Criteria in Solid Tumors 1.1. The primary estimate of ORR will be based on all patients randomized. A Cochran-Mantel-Haenszel test adjusting for the duration of durable response to the initial peptide receptor radionuclide therapy (durable response >= 24 months vs. < 24 months) at the time of randomization will be used to compare the objective response rates between two arms and sensitivity analysis adjusting for all three stratification factors at randomization will also be performed. |
Up to 3 years
|
|
Post progression survival (PPS)
時間枠:From objective progression on everolimus to objective progression or death from any cause after cross-over to receive 177Lu-DOTATATE, assessed up to 3 years
|
Median PPS and associated two-sided 90% confidence interval will be estimated using the Kaplan-Meier method. |
From objective progression on everolimus to objective progression or death from any cause after cross-over to receive 177Lu-DOTATATE, assessed up to 3 years
|
|
Time to second objective disease progression (PFS2)
時間枠:From randomization to objective tumor progression or death from any cause after the cross-over, assessed up to 3 years
|
Median PFS2 and associated two-sided 90% confidence interval will be estimated using the Kaplan-Meier method. |
From randomization to objective tumor progression or death from any cause after the cross-over, assessed up to 3 years
|
協力者と研究者
捜査官
- 主任研究者:Simron Singh、Canadian Cancer Trials Group
研究記録日
主要日程の研究
研究開始 (実際)
一次修了 (推定)
研究の完了 (推定)
試験登録日
最初に提出
QC基準を満たした最初の提出物
最初の投稿 (実際)
学習記録の更新
投稿された最後の更新 (実際)
QC基準を満たした最後の更新が送信されました
最終確認日
詳しくは
本研究に関する用語
追加の関連 MeSH 用語
その他の研究ID番号
- NCI-2023-00118
- U10CA180863 (米国 NIH グラント/契約)
- NCI-2023-00118 (レジストリ識別子:CTRP (Clinical Trial Reporting Program))
- CCTG-NE1 (その他の識別子:CTEP)
- CCTG-NE1 (その他の識別子:Canadian Cancer Trials Group)
個々の参加者データ (IPD) の計画
個々の参加者データ (IPD) を共有する予定はありますか?
IPD プランの説明
NCI is committed to sharing data in accordance with NIH policy. For more details on how clinical trial data is shared, access the link to the NIH data sharing policy page.
医薬品およびデバイス情報、研究文書
米国FDA規制医薬品の研究
米国FDA規制機器製品の研究
この情報は、Web サイト clinicaltrials.gov から変更なしで直接取得したものです。研究の詳細を変更、削除、または更新するリクエストがある場合は、register@clinicaltrials.gov。 までご連絡ください。 clinicaltrials.gov に変更が加えられるとすぐに、ウェブサイトでも自動的に更新されます。